Related Experiment Videos
Transplantation for myocarditis: a controversy revisited
Edward D Moloney1, Jim J Egan, Peter Kelly
1Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
Summary
Giant cell myocarditis (GCM) can recur years after heart transplantation, necessitating careful monitoring. While overall survival post-transplant for myocarditis is improving, specific conditions like GCM require vigilance for recurrence.
Area of Science:
- Cardiology
- Immunology
- Transplantation Science
Background:
- Myocarditis is a significant cause of end-stage heart failure and idiopathic dilated cardiomyopathy (IDC).
- Cardiac transplantation is a treatment for advanced heart failure due to myocarditis and IDC.
- Early data suggested poor outcomes for myocarditis patients post-transplant, but recent studies indicate similar survival rates to other transplant etiologies.
Observation:
- This case report details a 42-year-old male experiencing giant cell myocarditis (GCM) recurrence 8 years after cardiac transplantation.
- Certain myocarditis subtypes, such as cardiac sarcoidosis and GCM, are associated with an increased risk of post-transplant disease recurrence.
Findings:
- Overall survival after cardiac transplantation for myocarditis is comparable to other causes.
- Patients with specific conditions like GCM require enhanced surveillance for potential disease recurrence post-transplantation.
Implications:
- Cardiac transplantation is a viable option for select myocarditis patients, including those with GCM.
- Heightened surveillance is crucial for patients with GCM or cardiac sarcoidosis post-transplant to detect recurrence early.
- Further research is needed to understand and mitigate the risk of GCM recurrence after heart transplantation.